林红燕 简介

联系方式：ok138太阳集团中国官方网站-ok138太阳集团中国官方网站-生物工程系

江苏省常州市常州科教城天润科技大厦A座812，邮编213164

邮箱：hylin@cczu.edu.cn   

研究方向：

天然产物化学结构修饰与抗肿瘤分子药理

中药天然产物调控肠道微生物抑制结肠炎癌转变机理

中药天然产物分离提取、结构鉴定与生物活性

主要学习和工作经历：

2022.07至今     ok138太阳集团中国官方网站 ok138太阳集团中国官方网站             讲师

2019.12~2022.04   南京大学 生命科学学院       助理研究员

2016.12~2019.11   南京大学 生命科学学院       博士后

2011.09~2016.09   南京大学 生命科学学院       生物学博士（硕博连读）

2007.09~2011.06   ok138太阳集团中国官方网站 制药与生命科学学院  生物工程学士

承担研究课题：

1. 国家自然科学基金委员会, 青年项目, 21702100, 基于天然产物紫草素的抗肿瘤药物设计与研究, 2018-01至2020-12, 24万元, 已结题, 主持。

2. 中央高校基金(国家重点实验室平台项目), 020814380140, 紫草素抑制结肠炎向结肠癌转变的分子机制研究, 2020-01至2020-12, 19万元, 已结题, 主持。

3. 中央高校基金(青年基金培育项目), 020814380057, 基于天然产物紫草素的抗肿瘤药物设计与研究, 2017-01至 2017-12, 10万, 已结题, 主持。

近五年发表论文：

综述文章：

1.     王煊, 杨旻恺, 韩洪苇, 文钟灵, 陆桂华, 戚金亮, 林红燕*, 杨永华*. 紫草素-中药植物天然产物: 生物合成、遗传调控、结构修饰与医药功能.《中国科学Ÿ生命科学》, 2022, 52 (3): 347-372.

2.     林红燕, 王煊, 何聪, 周紫玲, 杨旻恺, 文钟灵, 韩洪苇, 杨永华. 中药植物紫草天然产物的生物合成及其功能研究进展,《遗传》, 2021, 45 (5): 459-472.

3.     Hanyue Qiu, Pengfei Wang, Hongyan Lin, Chengyi Tang, Hailiang Zhu, Yonghua Yang. Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents. Chemical Biology & Drug Design, 2018, 91: 681-690.

研究论文：

1.    Hongyan Lin,Ziling Zhou, Xiaopeng Ma, Qingqing Chen, Hongwei Han,Xiaoming Wang, Jinliang Qi*, Yonghua Yang*. One pot synthesis of aryl nitrilesfrom aromatic aldehydes in a water environment. RSC Advances, 2021, 11: 24232-24237.

2.    Yingying Ma, Xiaorong Yang, Hongwei Han, Zhongling Wen, Minkai Yang, Yahan Zhang, Jiangyan Fu, Xuan Wang, Tongming Yin, Guihua Lu, Jinliang Qi, Hongyan Lin*, Xiaoming Wang*, Yonghua Yang*. Design, synthesis and biological evaluation of anilide (dicarboxylic acid) shikonin esters as antitumor agents through targeting PI3K/Akt/mTOR signaling pathway. Bioorganic Chemistry, 2021, 111: 104872-104883.

3.     Hongwei Han, Wenxue Sun, Lu Feng, Zhongling Wen, Minkai Yang, Yingying Ma, Jiangyan Fu, Xiaopeng Ma, Xinhong Xu, Zhaoyue Wang, Tongming Yin, Xiaoming Wang, Guihua Lu, Jinliang Qi, Hongyan Lin*, Yonghua Yang*. Differential relieving effects of shikonin and its derivatives on inflammation and mucosal barrier damage caused by ulcerative colitis. PeerJ, 2021, 9: 10675-10690.

4.    Hongyan Lin, Hongwei Han, Yinsong Wang, Deliu He, Wenxue Sun, Lu Feng, Zhongling Wen, Minkai Yang, Guihua Lu*, Xiaoming Wang*, Jinliang Qi*, Yonghua Yang*. Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo. Chinese Medicine, 2020, 15: 23-36.

5.    Wenxue Sun, Hongwei Han, Minkai Yang, Zhongling Wen, Yinsong Wang, Jiangyn Fu, Yunting Lu, Mingyue Wang, Jiaxin Bao, Guihua Lu, Jinliang Qi*, Xiaoming Wang*, Hongyan Lin*, Yonghua Yang*. Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.Bioorganic & Medicinal Chemistry, 2019, 27: 115153-115169.

6.    Hongwei Han^#, Hongyan Lin^#, Deliu He, Yao Ren, Wenxue Sun, Li Liang, Meihang Du, Dengchao Li, Yichun Chu, Minkai Yang, Xiaoming Wang*, Yonghua Yang*. Novel podophyllotoxin derivatives as potential tubulin inhibitors: design, synthesis, and antiproliferative activity evaluation. Chemistry & Biodiversity, 2018, 15: 1800289-1800303.

7.    Hong-Yan Lin, Hong-Wei Han, Wen-Xue Sun, Yu-Shun Yang,Cheng-Yi Tang, Gui-Hua Lu, Jin-Liang Qi*, Xiao-Ming Wang*, Yong-Hua Yang*. Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors. European Journal of Medicinal Chemistry,2018, 144: 137-150.